Evidence Gaps in the Era of Non-Vitamin K Oral Anticoagulants

Overview

Journal J Am Heart Assoc

Specialty Cardiology & Vascular Diseases

Date 2018 Jan 28

PMID 29374049

Citations 16

Authors

Konstantinos N Aronis

Elaine M Hylek

Affiliations

Soon will be listed here.

Citing Articles

Management of severe traumatic brain injury in a rivaroxaban overdose: illustrative case.

Foertsch M, Beckett H, Dehne L, Janusz S, Ferioli S, Ngwenya L J Neurosurg Case Lessons. 2024; 8(23).

PMID: 39622047 PMC: 11616141. DOI: 10.3171/CASE24475.

Efficacy and Safety of Andexanet Alfa Versus Four Factor Prothrombin Complex Concentrate for Emergent Reversal of Factor Xa Inhibitor Associated Intracranial Hemorrhage: A Systematic Review and Meta-Analysis.

Sarhan K, Mohamed R, Elmahdi R, Mohsen Y, Elsayed A, Zayed D Neurocrit Care. 2024; .

PMID: 39379749 DOI: 10.1007/s12028-024-02130-y.

Efficacy and Safety of Direct Oral Anticoagulants versus Warfarin in Obese Patients (BMI ≥ 30 kg/m) with Atrial Fibrillation or Venous Thromboembolism: An Updated Systematic Review and Meta-Analysis.

Karakasis P, Ktenopoulos N, Pamporis K, Sagris M, Soulaidopoulos S, Gerogianni M J Clin Med. 2024; 13(13).

PMID: 38999350 PMC: 11242099. DOI: 10.3390/jcm13133784.

Safety and efficacy of direct oral anticoagulants in stroke prevention in patients with atrial fibrillation complicated with anemia and/or thrombocytopenia: a retrospective cohort study.

Xu W, Chen J, Wu S, Huang N, Chen X, Zhang W Thromb J. 2023; 21(1):118.

PMID: 37986173 PMC: 10662166. DOI: 10.1186/s12959-023-00563-7.

Management of Patients Treated with Direct Oral Anticoagulants in Clinical Practice and Challenging Scenarios.

Luca F, Oliva F, Abrignani M, Di Fusco S, Parrini I, Canale M J Clin Med. 2023; 12(18).

PMID: 37762897 PMC: 10531873. DOI: 10.3390/jcm12185955.

References

Schulman S, Kearon C, Kakkar A, Mismetti P, Schellong S, Eriksson H . Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med. 2009; 361(24):2342-52. DOI: 10.1056/NEJMoa0906598. View

Greiten L, McKellar S, Rysavy J, Schaff H . Effectiveness of rivaroxaban for thromboprophylaxis of prosthetic heart valves in a porcine heterotopic valve model. Eur J Cardiothorac Surg. 2013; 45(5):914-9. DOI: 10.1093/ejcts/ezt545. View

Girardi G, Redecha P, Salmon J . Heparin prevents antiphospholipid antibody-induced fetal loss by inhibiting complement activation. Nat Med. 2004; 10(11):1222-6. DOI: 10.1038/nm1121. View

McHorney C, Ashton V, Laliberte F, Germain G, Wynant W, Crivera C . Adherence to Rivaroxaban Compared with Other Oral Anticoagulant Agents Among Patients with Nonvalvular Atrial Fibrillation. J Manag Care Spec Pharm. 2017; 23(9):980-988. PMC: 10397742. DOI: 10.18553/jmcp.2017.23.9.980. View

Cohen A, Spiro T, Buller H, Haskell L, Hu D, Hull R . Rivaroxaban for thromboprophylaxis in acutely ill medical patients. N Engl J Med. 2013; 368(6):513-23. DOI: 10.1056/NEJMoa1111096. View

Raskob G, van Es N, Segers A, Angchaisuksiri P, Oh D, Boda Z . Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial. Lancet Haematol. 2016; 3(8):e379-87. DOI: 10.1016/S2352-3026(16)30057-6. View

Dunbar-Jacob J, Erlen J, Schlenk E, Ryan C, Sereika S, Doswell W . Adherence in chronic disease. Annu Rev Nurs Res. 2000; 18:48-90. View

Jaffer I, Stafford A, Fredenburgh J, Whitlock R, Chan N, Weitz J . Dabigatran is Less Effective Than Warfarin at Attenuating Mechanical Heart Valve-Induced Thrombin Generation. J Am Heart Assoc. 2015; 4(8):e002322. PMC: 4599481. DOI: 10.1161/JAHA.115.002322. View

Agnelli G, Buller H, Cohen A, Gallus A, Lee T, Pak R . Oral apixaban for the treatment of venous thromboembolism in cancer patients: results from the AMPLIFY trial. J Thromb Haemost. 2015; 13(12):2187-91. DOI: 10.1111/jth.13153. View

10.

Wang X, Tirucherai G, Marbury T, Wang J, Chang M, Zhang D . Pharmacokinetics, pharmacodynamics, and safety of apixaban in subjects with end-stage renal disease on hemodialysis. J Clin Pharmacol. 2015; 56(5):628-36. DOI: 10.1002/jcph.628. View

11.

Nojima J, Masuda Y, Iwatani Y, Suehisa E, Futsukaichi Y, Kuratsune H . Tissue factor expression on monocytes induced by anti-phospholipid antibodies as a strong risk factor for thromboembolic complications in SLE patients. Biochem Biophys Res Commun. 2007; 365(1):195-200. DOI: 10.1016/j.bbrc.2007.10.173. View

12.

Wells P, Theberge I, Bowdridge J, Forgie M, Carrier M . PO-41 - Rivaroxaban is effective therapy for high risk cancer patients with venous thromboembolic disease. Thromb Res. 2016; 140 Suppl 1:S191-2. DOI: 10.1016/S0049-3848(16)30174-8. View

13.

Kuwauchi S, Watanabe S, Abe K, Yamasaki M, Ito J, Kawazoe K . Thromboembolism in a patient with a mechanical mitral valve during anticoagulation with dabigatran etexilate. Ann Thorac Surg. 2013; 96(5):1863-4. DOI: 10.1016/j.athoracsur.2013.03.043. View

14.

Crowther M, Crowther M . Intensity of warfarin coagulation in the antiphospholipid syndrome. Curr Rheumatol Rep. 2010; 12(1):64-9. DOI: 10.1007/s11926-009-0070-9. View

15.

Tellor K, Patel S, Armbruster A, Daly M . Evaluation of the appropriateness of dosing, indication and safety of rivaroxaban in a community hospital. J Clin Pharm Ther. 2015; 40(4):447-51. DOI: 10.1111/jcpt.12288. View

16.

Prins M, Lensing A, Brighton T, Lyons R, Rehm J, Trajanovic M . Oral rivaroxaban versus enoxaparin with vitamin K antagonist for the treatment of symptomatic venous thromboembolism in patients with cancer (EINSTEIN-DVT and EINSTEIN-PE): a pooled subgroup analysis of two randomised controlled trials. Lancet Haematol. 2016; 1(1):e37-46. DOI: 10.1016/S2352-3026(14)70018-3. View

17.

Ezekowitz , James , Radford , Rickles , Redmond . Initiating and Maintaining Patients on Warfarin Anticoagulation: The Importance of Monitoring. J Cardiovasc Pharmacol Ther. 2000; 4(1):3-8. DOI: 10.1177/107424849900400102. View

18.

Kearon C, Akl E, Ornelas J, Blaivas A, Jimenez D, Bounameaux H . Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report. Chest. 2016; 149(2):315-352. DOI: 10.1016/j.chest.2015.11.026. View

19.

DeWald T, Becker R . The pharmacology of novel oral anticoagulants. J Thromb Thrombolysis. 2013; 37(2):217-33. DOI: 10.1007/s11239-013-0967-z. View

20.

Giannakopoulos B, Gao L, Qi M, Wong J, Yu D, Vlachoyiannopoulos P . Factor XI is a substrate for oxidoreductases: enhanced activation of reduced FXI and its role in antiphospholipid syndrome thrombosis. J Autoimmun. 2012; 39(3):121-9. DOI: 10.1016/j.jaut.2012.05.005. View